

The list of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method of facilitating vascular growth in cardiac muscle of a human subject in need of such treatment, comprising:  
inhibiting human EMAP II activity in said human subject by an amount effective to stimulate vascular growth in said cardiac muscle, wherein said inhibiting step is not carried out by administering a human EMAP II antisense oligonucleotide.
2. (Currently Amended) The method according to claim 1, wherein said inhibiting step is carried out by administering a compound that specifically binds to human EMAP II to said subject in an amount effective to stimulate vascular growth in said cardiac muscle.
3. (Currently Amended) The method according to claim 2, wherein said compound is an antibody that specifically binds to human EMAP II.
4. (Currently Amended) The method according to claim 1, wherein said inhibiting step is carried out by downregulating human EMAP II expression in said subject by an amount effective to stimulate vascular growth in said cardiac muscle.
5. (Canceled)
6. (Currently Amended) The method according to claim 1, wherein said inhibiting step is carried out by administering a human **[[an]]** EMAP II receptor antagonist to said subject in an amount effective to stimulate vascular growth in said cardiac muscle.
7. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with myocardial ischemia.

8. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with atherosclerosis.

9. (Previously Presented) The method according to claim 1, wherein said subject is afflicted with a myocardial disease.

10. (Previously Presented) The method according to claim 9, wherein said myocardial disease is cardiomyopathy or cardiac hypertrophy.

11. (Currently Amended) A method of facilitating vascular growth in cardiac muscle tissue of a human subject in need of such treatment, said method comprising:

administering to said human subject an active agent that inhibits human EMAP II activity in said subject by an amount effective to promote blood vessel formation in said cardiac muscle, wherein said active agent is not a human EMAP II antisense oligonucleotide.

12. (Currently Amended) The method according to claim 11, wherein said active agent is a compound that specifically binds to human EMAP II.

13. (Currently Amended) The method according to claim 12, wherein said compound is an antibody that specifically binds to human EMAP II.

14. (Currently Amended) The method according to claim 11, wherein said active agent is a compound that downregulates human EMAP II expression.

15. (Canceled)

16. (Currently Amended) The method according to claim 11, wherein said active agent is a human **[[an]]** EMAP II receptor antagonist.

In re: Schwarz  
Serial No.: 09/733,306  
Filed: December 8, 2000  
Page 4 of 7

17. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with myocardial ischemia.

18. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with atherosclerosis.

19. (Previously Presented) The method according to claim 11, wherein said subject is afflicted with a myocardial disease.

20-46. (Canceled)